

October 26, 2018

To

Listing Department,

NATIONAL STOCK EXCHANGE OF INDIA LIMITED

Exchange Plaza,

Bandra Kurla Complex, Bandra (E),

MUMBAI -400 051

Company Code No. AUROPHARMA

To

The Corporate Relations Department

**BSE LIMITED** 

Phiroz Jeejeebhoy Towers, 25th floor, Dalal Street,

MUMBAI -400 001

Company Code No. 524804

Dear Sir,

Sub: Board Meeting to consider the Un-audited Financial Results of the Company for the second quarter and half year ended 30th September, 2018.

We hereby inform pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 that a Meeting of the Board of Directors of the Company will be held on **Monday**, **12**<sup>th</sup> **November**, **2018** to consider, inter alia, the Unaudited Financial Results of the Company for the second quarter and half year ended 30<sup>th</sup> September, 2018 of the Financial Year 2018-19.

We further inform that at the Board Meeting, the Board will also consider the proposal of payment of Interim Dividend, if any, for the financial year 2018-19.

Please take the information on record.

Thanking you,

Yours faithfully, For AUROBINDO PHARMA LIMITED

**B. ADI REDDY** 

Company Secretary

